UTHR: United Therapeutics Corporation - Summary | Jitta

United Therapeutics Corporation

NASDAQ:UTHR

Price
$117.95
Loss Chance
51.8%
4.98JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
128 / 855
1,949 / 4,190
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (48)
Recent Business Performance (64)
Financial Strength (78)
Return to Shareholders (43)
Competitive Advantage (50)
Jitta Signs
Debt LevelLow Long Term Debt
Revenue and EarningEarning loss detected in 2019
Operating MarginDeclined
Recent Business PerformanceEarning decline 117.87% in the last year
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
4.98
100.00%
1.53
147.24%
2.41
515.34%
Biotechnology
7.40
35.01%
7.17
37.53%
6.97
50.30%
COMPANY DESCRIPTION
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and internationally. The company’s commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing OreniPro, RemoPro, Treprostinil Technosphere, Trevyent, Ralinepag, and Aurora-GT to treat PAH; LNG01 to treat IPF; Unexisome to treat BPD; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. The company has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop LNG01. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.